AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14603706 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0
Study 10676716 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 21
Study 10676716 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet treatment
Number of subjects: 21
Study 10169534 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate survey form
Number of subjects: 4056
Study 10169534 — intervention group
Group type: COMPARATOR
Intervention: Standard survey form
Number of subjects: 4056
Study 10169534 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate survey form Overall Value
Number of subjects: 4056
Study 8154263 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacrozym
Number of subjects: 0
Study 8154263 — intervention group
Group type: COMPARATOR
Intervention: Tears Naturale
Number of subjects: 0
Study 3014408 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-soluble contrast media
Number of subjects: 106
Study 3014408 — intervention group
Group type: COMPARATOR
Intervention: Oil-soluble contrast media
Number of subjects: 106
Study 30332353 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent and Child Enhancement (PACE) program
Number of subjects: 149
Study 30332353 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 149
Study 27507005 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose drink (0.75 g/kg body weight)
Number of subjects: 36
Study 27507005 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein drink (0.75 g/kg body weight)
Number of subjects: 36
Study 27507005 — intervention group
Group type: COMPARATOR
Intervention: Sucralose (control)
Number of subjects: 36
Study 24887106 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (N = 8)
Number of subjects: 14
Study 24887106 — intervention group
Group type: COMPARATOR
Intervention: Sedentary group (N = 6)
Number of subjects: 14
Study 24887106 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study 22265809 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent placement as a bridge to surgery (Group B)
Number of subjects: 86
Study 22265809 — intervention group
Group type: COMPARATOR
Intervention: Emergency surgical resection (Group A)
Number of subjects: 86
Study 20042442 — intervention group
Group type: COMPARATOR
Intervention: Forced Air (FA) warming
Number of subjects: 80
Study 20042442 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive-Polymer (RP) warming
Number of subjects: 80
Study 18341431 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical latanoprost (LA) administered once-daily for 3 months after switching from beta-blockers
Number of subjects: 60
Study 18341431 — intervention group
Group type: COMPARATOR
Intervention: Topical beta-blockers (carteolol hydrochloride, nipradilol, betaxolol hydrochloride) administered twice-daily for 3 months before switching to LA
Number of subjects: 60
Study 15980931 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched drink (n=20)
Number of subjects: 33
Study 15980931 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=13)
Number of subjects: 33
Study 12432966 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release Adderall 20 mg (formulation A)
Number of subjects: 41
Study 12432966 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release Adderall 20 mg (formulation B)
Number of subjects: 41
Study 12432966 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release Adderall 20 mg (formulation C)
Number of subjects: 41
Study 12432966 — intervention group
Group type: COMPARATOR
Intervention: SLI381 30 mg (intact capsule)
Number of subjects: 41
Study 12432966 — intervention group
Group type: COMPARATOR
Intervention: SLI381 30 mg (sprinkled in applesauce)
Number of subjects: 41
Study 9803648 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week exercise group (supervised aerobic sessions, 3 times per week)
Number of subjects: 146
Study 9803648 — intervention group
Group type: COMPARATOR
Intervention: 16-week health education group (instructed to exercise aerobically on their own, 3 times per week)
Number of subjects: 146
Study 8582462 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene napsylate 100 mg
Number of subjects: 12
Study 8582462 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene napsylate 200 mg
Number of subjects: 12
Study 8582462 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 12
Study 8582462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3407612 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg Zn/d supplementation for 28 days
Number of subjects: 53
Study 3407612 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 53
Study 29325446 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 60
Study 29325446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28246046 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive approach (group A)
Number of subjects: 157
Study 28246046 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach (group B)
Number of subjects: 157
Study 26169008 — intervention group
Group type: EXPERIMENTAL
Intervention: PolyScope (multimodular flexible ureteroscope)
Number of subjects: 360
Study 26169008 — intervention group
Group type: COMPARATOR
Intervention: URF P-5 (conventional flexible ureteroscope)
Number of subjects: 360
Study 26169008 — intervention group
Group type: EXPERIMENTAL
Intervention: PolyScope
Number of subjects: 360
Study 26169008 — intervention group
Group type: COMPARATOR
Intervention: URF P-5
Number of subjects: 360
Study 26169008 — intervention group
Group type: EXPERIMENTAL
Intervention: PolyScope and URF P-5
Number of subjects: 360
Study 23315607 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function assessment using the Montreal Cognitive Assessment (MoCA) at baseline during inpatient stay.
Number of subjects: 260
Study 21821810 — intervention group
Group type: COMPARATOR
Intervention: Pearl millet‐soybean meal diet (PM)
Number of subjects: 160
Study 21821810 — intervention group
Group type: COMPARATOR
Intervention: CTL + exogenous enzymes (CE)
Number of subjects: 160
Study 21821810 — intervention group
Group type: COMPARATOR
Intervention: PM + exogenous enzymes (PE)
Number of subjects: 160
Study 19247545 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial electrical stimulation
Number of subjects: 119
Study 19247545 — intervention group
Group type: COMPARATOR
Intervention: Active placebo device
Number of subjects: 119
Study 17367216 — intervention group
Group type: EXPERIMENTAL
Intervention: Halo cast (nonsurgical management)
Number of subjects: 40
Study 17367216 — intervention group
Group type: COMPARATOR
Intervention: Surgical management
Number of subjects: 40
Study 15148063 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 120
Study 15148063 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 120
Study 11601116 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic therapy (pool exercise therapy)
Number of subjects: 0
Study 9013436 — intervention group
Group type: EXPERIMENTAL
Intervention: High heart rate intensity exercise (HI, N = 8) - exercised at a mean heart rate of 163 bpm for 40 to 45 minutes approximately four times weekly.
Number of subjects: 15
Study 9013436 — intervention group
Group type: COMPARATOR
Intervention: Low heart rate intensity exercise (LI, N = 7) - exercised at a mean heart rate of 132 bpm for 40 to 45 minutes approximately four times weekly.
Number of subjects: 15
Study 8174448 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with neuropathy
Number of subjects: 187
Study 8174448 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with a history of foot ulceration
Number of subjects: 187
Study 8174448 — intervention group
Group type: COMPARATOR
Intervention: Non‐neuropathic patients
Number of subjects: 187
Study 8174448 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic age‐matched control subjects
Number of subjects: 187
Study 3928919 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA (valine, leucine, isoleucine) at 0.5 g/kg/day
Number of subjects: 36
Study 3928919 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA (valine, leucine, isoleucine) at 1.0 g/kg/day
Number of subjects: 36
Study 3928919 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg of essential and nonessential AA solution with a prevalence of BCAA
Number of subjects: 36
Study 3928919 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (Control group D)
Number of subjects: 36
Study 30721181 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysobact
Number of subjects: 102
Study 30721181 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 102
Study 27567493 — intervention group
Group type: EXPERIMENTAL
Intervention: IVACFLU-S 15μg hemagglutinin of each of the three strains in 0.5mL
Number of subjects: 60
Study 27567493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25330508 — intervention group
Group type: EXPERIMENTAL
Intervention: Propensity score techniques
Number of subjects: 0
Study 23083787 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg daily (titrated to 50 mg)
Number of subjects: 1658
Study 23083787 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 1658
Study 23083787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1658
Study 19903864 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment (4 weeks)
Number of subjects: 39
Study 19903864 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 39
Study 19903864 — intervention group
Group type: EXPERIMENTAL
Intervention: NTG-induced vasodilation
Number of subjects: 39
Study 18817955 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil 75 mg after dinner for 6 weeks
Number of subjects: 122
Study 17397979 — intervention group
Group type: EXPERIMENTAL
Intervention: Rightward optokinetic stimulation
Number of subjects: 0
Study 17397979 — intervention group
Group type: EXPERIMENTAL
Intervention: Leftward optokinetic stimulation
Number of subjects: 0
Study 17397979 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no stimulation)
Number of subjects: 0
Study 15018436 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 IU hCG
Number of subjects: 0
Study 15018436 — intervention group
Group type: COMPARATOR
Intervention: None (control)
Number of subjects: 0
Study 11429021 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (1 g tid) for 12 weeks after intravenous ganciclovir (5 mg/kg/day for 5-10 days)
Number of subjects: 155
Study 11429021 — intervention group
Group type: COMPARATOR
Intervention: Oral acyclovir (400 mg tid) for 12 weeks after intravenous ganciclovir (5 mg/kg/day for 5-10 days)
Number of subjects: 155
Study 11429021 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir
Number of subjects: 155
Study 11429021 — intervention group
Group type: COMPARATOR
Intervention: Oral acyclovir
Number of subjects: 155
Study 9261911 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage procedure for adjusting regression effect
Number of subjects: 0
Study 9261911 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of covariance model
Number of subjects: 0
Study 9261911 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed correlation structure model
Number of subjects: 0
Study 8262130 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide plus flutamide (250 mg p.o. t.i.d.)
Number of subjects: 603
Study 8262130 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide plus placebo
Number of subjects: 603
Study 8262130 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide plus flutamide (in patients with minimal disease and good performance status)
Number of subjects: 603
Study 8262130 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide plus placebo (in patients with minimal disease and good performance status)
Number of subjects: 603
Study 4023977 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled lignocaine
Number of subjects: 10
Study 31948455 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from teriparatide to alendronate (switch group)
Number of subjects: 48
Study 31948455 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous alendronate (ALD group)
Number of subjects: 48
Study 31948455 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 48
Study 30742829 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress induction
Number of subjects: 0
Study 30742829 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 0
Study 28882233 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime central apneas (CA)
Number of subjects: 525
Study 28882233 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime central apneas (CA)
Number of subjects: 525
Study 28882233 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour central apneas (CA)
Number of subjects: 525
Study 28882233 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime central apnea index (CAI)
Number of subjects: 525
Study 28882233 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime central apnea index (CAI)
Number of subjects: 525
Study 28882233 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour central apnea index (CAI)
Number of subjects: 525
Study 24906665 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis for children with dilating VUR
Number of subjects: 0
Study 24906665 — intervention group
Group type: COMPARATOR
Intervention: No treatment or placebo
Number of subjects: 0
Study 23496855 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 422
Study 23496855 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 422
Study 19883384 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC) - Lindynette® and Cilest®
Number of subjects: 19
Study 19883384 — intervention group
Group type: COMPARATOR
Intervention: Non-OC (control)
Number of subjects: 19
Study 19883384 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC)
Number of subjects: 19
Study 19281738 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent intravenous calcitriol
Number of subjects: 6
Study 19281738 — intervention group
Group type: COMPARATOR
Intervention: Intermittent oral calcitriol
Number of subjects: 6
Study 17002607 — intervention group
Group type: EXPERIMENTAL
Intervention: HE2000 (50 mg)
Number of subjects: 24
Study 17002607 — intervention group
Group type: EXPERIMENTAL
Intervention: HE2000 (50 mg or 100 mg)
Number of subjects: 24
Study 17002607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15575824 — intervention group
Group type: COMPARATOR
Intervention: Orbital floor methylprednisolone
Number of subjects: 60
Study 15575824 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-Tenon triamcinolone
Number of subjects: 60
Study 10778871 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanol esters added to the test meal
Number of subjects: 11
Study 9241012 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 238
Study 9241012 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 238
Study 7871057 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil pretreatment with diazepam
Number of subjects: 0
Study 7871057 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (BZ) without flumazenil pretreatment
Number of subjects: 0
Study 3952023 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen treatment
Number of subjects: 116
Study 3952023 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy
Number of subjects: 116
Study 31102719 — intervention group
Group type: EXPERIMENTAL
Intervention: VCTE
Number of subjects: 938
Study 31102719 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroMeter
Number of subjects: 938
Study 31102719 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroMeterVCTE
Number of subjects: 938
Study 31102719 — intervention group
Group type: EXPERIMENTAL
Intervention: FIB4-FMVCTE algorithm
Number of subjects: 938
Study 31102719 — intervention group
Group type: EXPERIMENTAL
Intervention: VCTE-FMVCTE algorithm
Number of subjects: 938
Study 31102719 — intervention group
Group type: EXPERIMENTAL
Intervention: FIB4-FMVCTE and VCTE-FMVCTE algorithms
Number of subjects: 938
Study 28970290 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Snare Polypectomy (CSP)
Number of subjects: 538
Study 28970290 — intervention group
Group type: COMPARATOR
Intervention: Hot Snare Polypectomy (HSP)
Number of subjects: 538
Study 26918924 — intervention group
Group type: EXPERIMENTAL
Intervention: Trèswhite Ortho (TWO)
Number of subjects: 40
Study 26918924 — intervention group
Group type: EXPERIMENTAL
Intervention: Trèswhite Supreme (TWS)
Number of subjects: 40
Study 24757668 — intervention group
Group type: EXPERIMENTAL
Intervention: verum iTBS (intermittent theta burst stimulation)
Number of subjects: 44
Study 24757668 — intervention group
Group type: COMPARATOR
Intervention: sham iTBS
Number of subjects: 44
Study 24757668 — intervention group
Group type: COMPARATOR
Intervention: healthy controls (HC)
Number of subjects: 44
Study 23007487 — intervention group
Group type: EXPERIMENTAL
Intervention: Full‐leg length compressive garment (76% Meryl Elastane, 24% Lycra)
Number of subjects: 22
Study 23007487 — intervention group
Group type: COMPARATOR
Intervention: Similar‐looking noncompressive placebo garment (92% Polyamide, 8% Lycra)
Number of subjects: 22
Study 20718734 — intervention group
Group type: EXPERIMENTAL
Intervention: Haem arginate (HA) infusion
Number of subjects: 15
Study 18456237 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-alpha-hydroxyprogesterone caproate (17OHPC)
Number of subjects: 80
Study 18456237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 16446690 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS) supplementation (3,600 mg x day‐1 for 14 days)
Number of subjects: 16
Study 16446690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11926348 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (17‐beta‐oestradiol, norethisterone acetate, TTS, Estracomb Novartis)
Number of subjects: 76
Study 11926348 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hormonal therapy)
Number of subjects: 76
Study 11926348 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 76
Study 9666905 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychophysical measurements for visual acuity (VA)
Number of subjects: 0
Study 9666905 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychophysical measurements for contrast sensitivity (CS)
Number of subjects: 0
Study 9666905 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychophysical measurements for colour vision
Number of subjects: 0
Study 9666905 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity (VA) and colour vision tests
Number of subjects: 0
Study 9666905 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening tests for advanced levels of background DR
Number of subjects: 0
Study 7700657 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient exercise program incorporating interesting, purposeful activities
Number of subjects: 0
Study 7700657 — intervention group
Group type: COMPARATOR
Intervention: Simple home program of head movements
Number of subjects: 0
Study 2754149 — intervention group
Group type: COMPARATOR
Intervention: Metaproterenol sulfate aerosol (MPA) inhalation and placebo injection
Number of subjects: 100
Study 2754149 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine injection (EPI) and inhaled placebo
Number of subjects: 100
Study 2754149 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover comparison regimen after initial treatment
Number of subjects: 100
Study 1278718 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam plus hyoscine butylbromide
Number of subjects: 10
Study 1278718 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 10
Study 1278718 — intervention group
Group type: COMPARATOR
Intervention: Control (secretin and cholecystokinin without drugs)
Number of subjects: 10
Study 31863497 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentors with higher levels of depressive symptoms
Number of subjects: 340
Study 31863497 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentors who experienced higher levels of early life stress
Number of subjects: 340
Study 31174256 — intervention group
Group type: EXPERIMENTAL
Intervention: PM2.5 exposed group
Number of subjects: 280
Study 31174256 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 280
Study 28383476 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital transfusion (PHT) of plasma and/or RBCs
Number of subjects: 1058
Study 28383476 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid resuscitation (Control)
Number of subjects: 1058
Study 28383476 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital transfusion (PHT)
Number of subjects: 1058
Study 26491119 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein (CAS)
Number of subjects: 10
Study 26491119 — intervention group
Group type: COMPARATOR
Intervention: Whey protein (WHE)
Number of subjects: 10
Study 26491119 — intervention group
Group type: COMPARATOR
Intervention: α-lactalbumin-enriched whey protein (LAC)
Number of subjects: 10
Study 24040949 — intervention group
Group type: EXPERIMENTAL
Intervention: MMA
Number of subjects: 27
Study 24040949 — intervention group
Group type: EXPERIMENTAL
Intervention: MMA-Drep
Number of subjects: 27
Study 21790503 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 0
Study 21790503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18803564 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 0
Study 18803564 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drugs (AAD)
Number of subjects: 0
Study 16699361 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies (newspaper advertisements, flyers)
Number of subjects: 0
Study 16699361 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention strategies (flexible scheduling, frequent contact, caring environment)
Number of subjects: 0